Nisa Investment Advisors LLC Acquires 8,294 Shares of Amgen Inc. $AMGN

Nisa Investment Advisors LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 5.2% in the third quarter, Holdings Channel reports. The institutional investor owned 167,256 shares of the medical research company’s stock after acquiring an additional 8,294 shares during the period. Nisa Investment Advisors LLC’s holdings in Amgen were worth $70,500,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. grew its position in shares of Amgen by 4.8% during the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after acquiring an additional 2,261,544 shares during the period. State Street Corp increased its stake in shares of Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Amgen by 12.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock worth $1,952,156,000 after purchasing an additional 605,928 shares during the period. Bank of America Corp DE bought a new position in Amgen in the 2nd quarter worth $1,831,903,000. Finally, Amundi lifted its position in Amgen by 15.2% during the second quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock valued at $1,408,715,000 after purchasing an additional 512,883 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on AMGN shares. Morgan Stanley cut their price target on Amgen from $362.00 to $359.00 and set an “equal weight” rating for the company in a report on Wednesday, October 7th. Robert W. Baird upped their price target on Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. UBS Group raised their price objective on Amgen from $430.00 to $470.00 and gave the stock a “buy” rating in a research note on Friday, October 9th. Guggenheim lowered their price objective on Amgen from $388.00 to $378.00 and set a “neutral” rating on the stock in a research report on Tuesday, October 13th. Finally, HSBC downgraded Amgen from a “buy” rating to a “hold” rating and cut their price objective for the company from $445.00 to $425.00 in a research note on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $387.93.

Insider Activity at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 6,222 shares of company stock worth $2,540,926. Company insiders own 0.85% of the company’s stock.

Amgen Stock Performance

NASDAQ AMGN opened at $438.94 on Wednesday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. Amgen Inc. has a twelve month low of $288.00 and a twelve month high of $447.03. The business has a 50-day moving average price of $416.19 and a 200-day moving average price of $376.06. The firm has a market cap of $237.30 billion, a price-to-earnings ratio of 19.00, a price-to-earnings-growth ratio of 3.11 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same quarter last year, the company earned $6.02 EPS. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts predict that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s dividend payout ratio (DPR) is 62.65%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive Tezspire Phase 3 results: Amgen and AstraZeneca reported that Tezspire produced statistically significant and clinically meaningful improvements in eosinophilic esophagitis, including sustained symptom improvement and histologic remission through 52 weeks. The data could expand Tezspire’s commercial opportunity beyond severe asthma. Tezspire Phase 3 results
• Positive Sentiment: Upcoming oncology presentation: Amgen will host an investor webcast during the European Society for Medical Oncology Congress on October 24. New cancer-drug data could provide additional visibility into the company’s pipeline and growth prospects. Amgen ESMO 2026 presentation
• Positive Sentiment: Higher analyst valuation: Goldman Sachs raised its price target for AMGN to $481, signaling potential upside from recent trading levels and reinforcing improving sentiment toward the company. Goldman Sachs raises Amgen price target
• Positive Sentiment: Strong financial performance: Amgen recently exceeded consensus estimates for quarterly revenue and earnings per share, with revenue up 9.5% year over year. Investors are increasingly viewing the company’s diversified portfolio as capable of delivering renewed growth.
• Neutral Sentiment: Compared with Bristol Myers Squibb, Amgen offers stronger recent top-line growth, while Bristol Myers has a lower valuation and substantial free cash flow. The comparison highlights AMGN’s growth appeal but also its relatively fuller valuation. Amgen versus Bristol Myers Squibb
• Negative Sentiment: At roughly 27 times earnings, AMGN is not a deep-value healthcare stock, and its high debt-to-equity ratio increases sensitivity to execution and pipeline setbacks. Investors still need evidence that newer products can sustain growth as mature medicines face competition.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.